Poseida Therapeutics (PSTX) Earnings Date & Reports
Get AI intraday signals
A.I. Advisor
published Earnings
PSTX is expected to report earnings to rise 21.87% to -38 cents per share on November 07
Q3'24
Est.
$-0.39
Q2'24
Beat
by $0.09
Q1'24
Beat
by $0.17
Q4'23
Beat
by $0.12
Q3'23
Missed
by $0.06
The last earnings report on August 05 showed earnings per share of -31 cents, beating the estimate of -40 cents. With 658.03K shares outstanding, the current market capitalization sits at 281.69M.
a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors